Skip to main content

Advertisement

Table 2 Studies reporting PAI-1 activity levels (IU/mL) and major adverse cardiovascular events and restenosis

From: Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

  Event No Event
Reference Year Study Design Follow-up (months) Population of interest N PAI-1 Activity (U/mL) Range Death MI Restenosis N PAI-1 Activity (U/mL) Range
Sane et al. [50] 1991 Cohort 24 Fibrinolytics 28 17 16 n/a n/a 28 328 19 21
Shah et al. [72] 1992 Cohort 9 Elective PCI 28 8 7.1 n/a n/a 28 40 12 8
Gray et al. [73] 1993 Cohort 0.1 MI 13 20.6 11 n/a 13 n/a 85 20.1 7.9
Malmberg et al. [74] 1994 Case-Control 90 MI 53 23.75 13.34 20 33 n/a 55 18 10.97
Brack et al. [75] 1994 Cohort 4 Elective PCI 16 4.63 4.71 n/a n/a 16 30 5.77 5.06
Nordt et al. [54] 1998 Cohort 12 Fibrinolytics 5 8.7 8.3 n/a 5 n/a 26 9.9 8.2
Jansson et al. [76] 1998 Cohort 120 MI 54 9.1 5.1 54 n/a n/a 69 10.6 7.1
Wiman et al. [77] 2000 Case-Control 3 MI 61 22.1 17.5 n/a 61 n/a 95 18.2 16.5
Wiman et al. [77] 2000 Case-Control 3 Ml 25 15.4 13.6 n/a 25 n/a 38 17.8 12.4
Prisco et al. [78] 2001 Cohort 18 MI 18 11.27 7.64 n/a n/a 18 36 15.8 27.49
Prisco et al. [78] 2001 Cohort 18 Elective PCI 6 8.33 8.1 n/a n/a 6 42 7.57 9.52
Sargento et al. [79] 2003 Cohort 12 MI 7 6.34 1.56 5 2 n/a 80 4.47 1.84
Marcucci et al. [19] 2006 Case-Control 22 2 MI 109 22 9.09 54 55 n/a 411 24.25 10.63
Schoebel et al. [80] 2008 Cohort 2 MI 18 3.7 1.8 n/a n/a 18 42 5.3 3.2
  1. Wiman et al. [77] is presented twice as data for men and women were reported separately